Test Price
2,800 AED✅ Home Collection Available
SARS2 Gene NGS Test for HUPRA Syndrome – Hyperuricemia, Pulmonary Hypertension, Renal Failure & Alkalosis in UAE | 2,800 AED
Executive Summary & Core Metrics
Definitive next-generation sequencing (NGS) analysis of the mitochondrial seryl-tRNA synthetase gene for molecular confirmation of HUPRA syndrome. This test delivers 99.9% diagnostic sensitivity through ISO-accredited laboratory processing and includes pre-test pedigree assessment and post-test telephonic guidance by a DHA-licensed consultant medical geneticist.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Interpretation by DHA-Licensed Consultant Medical Geneticist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SARS2 Gene NGS Test is a definitive molecular diagnostic for HUPRA syndrome – a rare mitochondrial disorder characterised by hyperuricemia, pulmonary hypertension, renal failure, and alkalosis. The assay detects pathogenic single-nucleotide variants and small indels across all coding exons and splice junctions of the SARS2 gene using next-generation sequencing on an Illumina platform. Results are interpreted against ACMG/AMP guidelines and correlated with clinical presentation, renal function, and pulmonary haemodynamics.
This test empowers clinicians and families with precise genetic confirmation, guides nephroprotective surveillance, informs pulmonary hypertension management, and enables recurrence risk counselling for future pregnancies.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Methodology | NGS (Next-Generation Sequencing, Illumina) | Sanger Sequencing (single-exon) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Pre-Test Genetic Counselling | Included (pedigree chart & risk assessment) | Often not provided |
| Post-Test Specialist Interpretation | Telephonic guidance with DHA-licensed consultant medical geneticist | Written report only |
| Price (AED) | 2,800 | 3,200 – 4,500 |
Physician Insight & Safety Protocols
Insight from Lina Osama Zaki Quteineh – Consultant Medical Genetics (DHA Registration ID: 9294403)
“Molecular confirmation of a pathogenic SARS2 variant provides the cornerstone for accurate prognostic counselling and targeted surveillance in HUPRA syndrome. However, a negative sequencing result does not exclude a mitochondrial disorder; clinicians must always integrate biochemical markers, renal sonography, and pulmonary function studies. Early genetic diagnosis enables initiation of nephroprotective therapy and optimization of pulmonary vasodilator strategies before irreversible end-organ damage occurs.”
Advisory – Medication Continuation
Do not discontinue or alter prescribed therapy without consulting your managing physician. Genetic test results are not a substitute for ongoing clinical management and should never be used as the sole basis for medication changes.
Exclusion Criteria & Emergency Red Flags
- Not for emergency diagnosis of acute renal failure, hypertensive crisis, or acute respiratory distress.
- Unsuitable for asymptomatic individuals without clinical suspicion, family history, or biochemical evidence of HUPRA syndrome.
- Requires valid informed consent per Federal Decree-Law No. 4 of 2016 on Medical Liability and the UAE Personal Data Protection Law.
- For minors (<18 years), additional parental consent is mandatory under UAE child protection statutes.
- ER Red Flags: sudden severe dyspnoea, crushing chest pain, systolic BP >180 mmHg, anuria for >12 hours – seek immediate emergency medical attention.
Patient FAQ & Clinical Guidance
1. What is the purpose of the SARS2 gene test and who should consider it?
This NGS-based test identifies pathogenic mutations in the SARS2 gene to confirm or exclude a diagnosis of HUPRA syndrome. It is indicated for individuals with unexplained concurrent hyperuricemia, pulmonary hypertension, and renal impairment, or those with a family history suggestive of mitochondrial disease. A pre-test genetic counselling session is provided to construct a three-generation pedigree and assess inheritance risk.
2. How is the sample collected and what is the expected turnaround time?
A peripheral whole blood sample or extracted DNA is collected by our ISO-accredited phlebotomist during a home visit. VIP mobile service operates daily from 8 AM to 11 PM with temperature-controlled cold-chain transport to the Dubai laboratory. Results are delivered within 3 to 4 weeks, followed by a telephonic interpretation session with a DHA-licensed consultant medical geneticist.
3. Is this test covered by insurance and what legal protections apply?
Insurance eligibility is verified directly via WhatsApp and billing is facilitated under UAE health insurance frameworks. All genetic data is processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The laboratory holds ISO 9001:2015 certification (Certificate: INT/EGQ/2509DA/3139), and consent procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability.
4. What does a positive or negative result mean for my health management?
A positive result confirms a molecular diagnosis of HUPRA syndrome and enables targeted surveillance and therapeutic planning. A negative result reduces but does not eliminate the possibility of a mitochondrial disorder; additional biochemical and genetic workup may be indicated. In both scenarios, the consulting geneticist will provide a personalised management roadmap including nephrology and pulmonology referral recommendations.
UAE Regulatory & Data Privacy Adherence
Your genetic data is protected under the highest standards of UAE law and international laboratory practice. This test is performed at DNA Labs UAE, a DHA-licensed facility (License No. 1143), and complies fully with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing collection, processing, and storage of genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating electronic health records and telemedicine components.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring informed consent, clinical safety, and patient rights throughout the testing pathway.
- ISO 9001:2015 Quality Management System (Certificate: INT/EGQ/2509DA/3139).
All samples are processed in a secure, access-controlled laboratory environment, and genetic results are disclosed only to the ordering physician and the patient following verified identity protocols.
Clinical & Logistical Metadata
| Test Name | SARS2 Gene NGS Test for HUPRA Syndrome |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina Platform |
| ICD-10-CM Code | E79.0, I27.0, N19, E87.3 |
| LOINC Code | 81264-9 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians